RyCarma Therapeutics, Inc.
PrivateLast Round
Corporate Funding
Dec 1, 2024
Est. Valuation
$70M
Total Funding Raised
$48.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
RyCarma Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Corporate Funding round in December 2024.
RyCarma Therapeutics, Inc. is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RyCarma Therapeutics, Inc. Comparables
Compare RyCarma Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Medera | 71% | |
| Windtree Therapeutics, Inc. | 71% | |
| Cardurion Pharmaceuticals | 69% |
For institutional investors. Book with your work email.
RyCarma Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Dec 1, 2024 | ||||
| Series B | Dec 20, 2021 | ||||
| Grant | Apr 17, 2013 | ||||
| VC Round | Aug 24, 2011 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
RyCarma Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Corporate Funding, Series B |
| Pontifax Venture Capital | Series B, Corporate Funding |
| Muscular Dystrophy Association | Grant |
| Kurma Partners | Series B, Corporate Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 44% MoM.
- Apr 18, 2026
Monthly visitors increased 141% MoM.
For institutional investors. Book with your work email.
RyCarma Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RyCarma Therapeutics, Inc.'s valuation, stock price, and market status.
Is RyCarma Therapeutics, Inc. a public or private company?
RyCarma Therapeutics, Inc. is a private company.
What is the current stock price of RyCarma Therapeutics, Inc.?
RyCarma Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks RyCarma Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RyCarma Therapeutics, Inc. worth (valuation)?
RyCarma Therapeutics, Inc.'s valuation is estimated at $70.0M based on funding round data.
Can I buy RyCarma Therapeutics, Inc. stock?
RyCarma Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RyCarma Therapeutics, Inc.'s last funding round?
RyCarma Therapeutics, Inc.'s most recent funding round was Corporate Funding on December 1, 2024.
Who are the main investors in RyCarma Therapeutics, Inc.?
Key investors in RyCarma Therapeutics, Inc. include Forbion.
Will RyCarma Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for RyCarma Therapeutics, Inc..
How can I track RyCarma Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in RyCarma Therapeutics, Inc.'s shares on secondary markets.